Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D53CGK
|
|||
| Drug Name |
PC14586
|
|||
| Drug Type |
Small interfering RNA
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1/2 | [1] | |
| Company |
PMV Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | P53 Y220C mutant (TP53 Y220C) | Target Info | Reactivator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04585750) The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of PMV Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.